Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro

AIM: To find new kinase inhibitors that overcome the imatinib resistance in treatment of chronic myeloid leukemia (CML), we synthesized C817, a novel derivative of curcumin, and tested its activities against wild-type (WT) and imatinib-resistant mutant Abl kinases, as well as in imatinib-sensitive a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Acta Pharmacol Sin
Päätekijät: Wu, Li-xian, Wu, Ying, Chen, Rui-jia, Liu, Yang, Huang, Li-sen, Lou, Li-guang, Zheng, Zhi-hong, Chen, Yuan-zhong, Xu, Jian-hua
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2014
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4647898/
https://ncbi.nlm.nih.gov/pubmed/24487968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2013.180
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia